1 Letterman Dr
2 articles with Sonoma BioTherapeutics
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
Company founded by four pioneers of Treg cell biology and cell therapy and financed by a syndicate of leading biotech investors
2/6/2020Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.